Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Antibody engineering is increasingly being used to influence the properties of monoclonal antibodies to improve their biotherapeutic potential. One important aspect of this is the modulation of glycosylation as a strategy to improve efficacy. Here, we describe mutations of Y407 in the CH3 domain of IgG1 and IgG4 that significantly increase sialylation, galactosylation, and branching of the N-linked glycans in the CH2 domain. These mutations also promote the formation of monomeric assemblies (one heavy-light chain pair). Hydrogen-deuterium exchange mass spectrometry was used to probe conformational changes in IgG1-Y407E, revealing, as expected, a more exposed CH3-CH3 dimerization interface. Additionally, allosteric structural effects in the CH2 domain and in the CH2-CH3 interface were identified, providing a possible explanation for the dramatic change in glycosylation. Thus, the mutation of Y407 in the CH3 domain remarkably affects both antibody conformation and glycosylation, which not only alters our understanding of antibody structure, but also reveals possibilities for obtaining recombinant IgG with glycosylation tailored for clinical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc
Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C., & Ravetch, J. V. (2008) · Science · doi:10.1126/science.1154315 · Cited by 849
Control of Recombinant Monoclonal Antibody Effector Functions by Fc N‐Glycan Remodeling in Vitro
Hodoniczky, J., Zheng, Y. Z., & James, D. C. (2005) · Biotechnology Progress · doi:10.1021/bp050228w · Cited by 393 · cited 7×
“Application of fully α(2,6)-sialylated IgG in the clinic therefore seems attractive, but the portion of sialylated human IgG in IVIG is very low, as is the sialylation of recombinantly produced IgG.”
BackgroundInfluential
Cited by
James, E. I., Murphree, T. A., Vorauer, C., Engen, J. R., & Guttman, M. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00279 · Cited by 305
MS-Based Allotype-Specific Analysis of Polyclonal IgG-Fc N-Glycosylation
Sénard, T., Gargano, A. F. G., Falck, D., de Taeye, S. W., Rispens, T., Vidarsson, G., Wuhrer, M., Somsen, G. W., & Domínguez-Vega, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02049 · Cited by 292
Glycoproteomics: A Balance between High-Throughput and In-Depth Analysis
Yang, Y., Franc, V., & Heck, A. J. R. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2017.04.010 · Cited by 122
Self-citationProduction of α2,6-sialylated IgG1 in CHO cells
Raymond, C., Robotham, A., Spearman, M., Butler, M., Kelly, J., & Durocher, Y. (2015) · mAbs · doi:10.1080/19420862.2015.1029215 · Cited by 106
Harvey, D. J. (2018) · Mass Spectrometry Reviews · doi:10.1002/mas.21530 · Cited by 61
Metadata
- Authors
- Rose, R. J., van Berkel, P. H. C., van den Bremer, E. T. J., Labrijn, A. F., Vink, T., Schuurman, J., Heck, A. J. R., & Parren, P. W. H. I.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2013-03
- Volume
- 5
- Issue
- 2
- Pages
- 219-228
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2097680693
- Cited by
- 67
- References
- 5
- FWCI
- 7.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.